Article
A biopsy-based genomic assay that would discriminate between aggressive prostate cancer and indolent disease to guide treatment decisions is under development.
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Study shows value of precision-based approaches in prostate cancer
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Patient selection for cytoreductive nephrectomy in 2025
SBRT may offer a safe alternative to CFRT after prostatectomy